Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen – A new hybrid design paradigm
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (15) , 4428-4440
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Role of SUMOylation in Full AntiestrogenicityMolecular and Cellular Biology, 2012
- HDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsImmunology & Cell Biology, 2011
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerBritish Journal of Cancer, 2011
- An o-Aminoanilide Analogue of 1α,25-Dihydroxyvitamin D3 Functions as a Strong Vitamin D Receptor AntagonistJournal of Medicinal Chemistry, 2010
- Chemical phylogenetics of histone deacetylasesNature Chemical Biology, 2010
- Selective Estrogen Receptor Modulator Delivery of Quinone Warheads to DNA Triggering Apoptosis in Breast Cancer CellsACS Chemical Biology, 2009
- Differential regulation of connective tissue growth factor in renal cells by histone deacetylase inhibitorsJournal of Cellular and Molecular Medicine, 2009
- The many roles of histone deacetylases in development and physiology: implications for disease and therapyNature Reviews Genetics, 2009
- Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonistProceedings of the National Academy of Sciences, 2008
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971